|
Welcome to the fifth issue of PharmaView!
Pharmaceutical
Marketers are facing increasing pressures: increasing competition; squeezed
margins; shrinking budgets; more to do and less time to do it. It’s becoming
difficult to work any harder, and of course it's always better to work smarter.
Therefore we bring you the PharmaView.
PharmaView
is a biweekly educational and informative newsletter for improving readers’ marketing
knowledge and reporting the latest news in the pharma industry. It also provides
great opportunities to exchange ideas, network and be recognized among your
peers in the industry.
Through
PharmaView, you can:
Learn peer’s
experience in pharma marketing
Stay in touch with
what’s happening in pharmaceutical marketing today
Be on the
pioneering edge of pharmaceutical marketing
Have networking /
idea exchange opportunities
About Us
Integrating local
knowledge with international perspective,
Consultech Co. Ltd.
offers its clients and prospects one-lstop solutions with sales
and marketing consultancy, advertising and promotion strategies.
Consultech is an affiliate
company of Omnicom, the world's largest advertising and communications
holding company.
FDA Approves New Treatment for Diabetes
The Food and Drug
Administration (FDA) announced today the approval of Januvia (sitagliptin
phosphate) Tablets, the first diabetes treatment approved in a new class of
drugs known as DPP-4 inhibitors that enhances the body's own ability to lower
elevated blood sugar.
Oct. 17, 2006
FDA Approves Expanded Use of Treatment for Patients With Severe Alzheimer's
Disease
The Food and Drug
Administration (FDA) today approved Aricept (donepezil hydrochloride) for the
treatment of severe dementia in patients with Alzheimer's Disease.
Oct. 13, 2006
FDA Approves New Combination Therapy for Lung Cancer
The U.S. Food and Drug
Administration (FDA) approved the use of Avastin (bevacizumab) in combination
with carboplatin and paclitaxel for the initial systemic treatment of patients
with unresectable, locally advanced, recurrent or metastatic, non-squamous,
non-small cell lung cancer. This approval was based on an improvement in
survival time when Avastin was added to a standard chemotherapy regimen.
Oct. 12, 2006
KOL relationship
management should be an essential component of any pharma brand team
Marketing effectively to
physicians in today's pharmaceutical industry is more important than ever.
No longer can companies rely solely on DTC and sales force efforts to
increase drug and therapeutics revenue.
Oct. 01, 2006
Ahead-of-the-lcurve
brand teams are bringing in medical experts with marketing knowledge
Today's brand teams play for
extremely high stakes when fighting off competitor challenges. From attacks on
clinical-trial interpretation (witness Vioxx), unexpected toxicity (Tysabri),
and explosive social issues (Gardasil) to oceans of emerging data (new
cholesterol medications such as Zetia and Pfizer's investigational drug
torcetrapib), brand teams need to interact with medical and scientific
professionals more than ever.
Sep 01, 2006
New legislation
forces drug companies to rethink marketing and sales initiatives
The regulatory environment
for the pharmaceutical industry never has been more burdensome than it is today.
Recently, the federal government increased the number of penalties it issues
against pharma companies; FDA announced sample inspections for this year; and
the Drug Enforcement Administration has increased monetary penalties against the
industry.
Jun 01, 2006
Merck's cervical cancer vaccine on sale in Europe
Merck & Co Inc's Gardasil,
the first vaccine to prevent cervical cancer, was launched in Britain and
Ireland on Tuesday in the latest phase of an unusually rapid rollout for the new
product.
Oct 17, 2006
Eli Lilly to acquire Icos for $2.1 billion
Eli Lilly & Co. said on Tuesday it has agreed
to acquire the biotechnology company Icos Corp. for $2.1 billion to gain full
rights to the erectile dysfunction drug Cialis.
Oct 17, 2006
Merck Starts
Diabetes Race
Merck
has won approval from the U.S. Food and Drug Administration for its diabetes
pill Januvia, setting the stage for one of the most-watched drug marketing duels
in years.
Oct 17, 2006
Doctors set to use new diabetes drugs: survey
As the first two drugs in a
new diabetes-treatment class near U.S. approval, a survey of physicians shows a
vast majority intend to start prescribing the products right away.
Oct 16, 2006
Please feel free to offer
your opinions and advices about PharmaView in order to better our
services. Should you have any comments, or if you want to unsubscribe from PharmaView, please send us an
email: pharmaview@Consultech.com.cn
. Thank you!
|
